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Abstract
Background: Recent studies reported the association between SLCO1B1 polymorphisms and the development of
statin-induced myopathy. In the scenario of the Brazilian population, being one of the most heterogeneous in the
world, the main aim here was to evaluate SLCO1B1 polymorphisms according to ethnic groups as an initial step for
future pharmacogenetic studies.
Methods: One hundred and eighty-two Amerindians plus 1,032 subjects from the general urban population were
included. Genotypes for the SLCO1B1 rs4149056 (c.T521C, p.V174A, exon 5) and SLCO1B1 rs4363657 (g.T89595C,
intron 11) polymorphisms were detected by polymerase chain reaction followed by high resolution melting
analysis with the Rotor Gene 6000
® instrument.
Results: The frequencies of the SLCO1B1 rs4149056 and rs4363657 C variant allele were higher in Amerindians
(28.3% and 26.1%) and were lower in African descent subjects (5.7% and 10.8%) compared with Mulatto (14.9%
and 18.2%) and Caucasian descent (14.8% and 15.4%) ethnic groups (p < 0.001 and p < 0.001, respectively).
Linkage disequilibrium analysis show that these variant alleles are in different linkage disequilibrium patterns
depending on the ethnic origin.
Conclusion: Our findings indicate interethnic differences for the SLCO1B1 rs4149056 C risk allele frequency among
Brazilians. These data will be useful in the development of effective programs for stratifying individuals regarding
adherence, efficacy and choice of statin-type.
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Background
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coen-
zyme A (HMG-CoA), are widely prescribed drugs to
reduce cardiovascular morbidity and mortality and their
use is well tolerated by the majority of patients [1,2].
Nonetheless, statins can lead to myopathy (i.e., muscle
pain) with symptoms ranging from mild myalgia without
elevated serum creatine kinase to fatal rhabdomyolysis
(i.e., muscle breakdown and myoglobin release) [2,3]. In
clinical practice, the incidence of mild statin-induced
side effects (about 5-10%) appears to be greater than in
controlled trials and the mechanisms by which statins
lead to myopathy remain unclear. However, studies have
suggested that blood statin concentrations, daily dose,
female gender, hepatic or renal dysfunction, and conco-
mitant drugs are all predictors of statin-induced myopa-
thy [4-7].
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tion between SLCO1B1 polymorphisms and the develop-
ment of musculoskeletal side effects [8-10]. The
SLCO1B1 gene (Gene ID: 10599) encodes the organic
anion-transporting polypeptide 1B1 (OATP1B1) that
plays a crucial role in the hepatic uptake and clearance of
albumin-bound organic compounds [11]. In particular,
the SLCO1B1 rs4149056 functional polymorphism (c.
T521C, p.V174A) in exon 5, leads to higher statin circu-
lating concentration [12,13]. SLCO1B1 rs4149056 was
associated with an odds ratio for myopathy of 4.5 (95%
CI, 2.6 to 7.7) per copy of the C allele and 16.9 (95% CI,
4.7 to 61.1) among CC homozygotes as compared with
the TT genotype, in a genome-wide association study
plus replication in a trial of simvastatin 40 mg daily invol-
ving 20,000 participants [9]. The frequencies of SLCO1B1
polymorphisms vary significantly among different world-
wide populations, leaving the impact of pharmacogenetic
testing for these variants extremely dependent on a parti-
cular population genetic architecture.
The Brazilian population is one of the most heteroge-
neous in the world, being a mixture of different ethnic
groups, composed mainly of European (Caucasian des-
cent), African descent and Amerindians [14,15]. Thus,
the main aim of the present study was to evaluate the
SLCO1B1 polymorphisms according to ethnic groups as
an initial step for future pharmacogenetic studies and
screening programmes.
Methods
Study Population
This study included 1,032 subjects of the general urban
population selected from the Hearts of Brazil Project
(HBP) [16]. The universe of the HBP consisted in the
set of inhabitants of Brazilian urban centers with more
than 100,000 inhabitants. The HBP sample plan was cal-
culated as 2,500 interviews, distributed in 72 cities from
the 5 regions of the country proportionally to the num-
ber of inhabitants, per sex and age range, based on data
from IBGE (Brazilian Institute of Geography and Statis-
tic). In the selected cities, the “households” constituted
the second-stage units, with one interview per house-
hold. Subjects were separated in self-identified sub-
groups according to ethnicity, as Caucasian descent,
African descent, or Mulattos (considered mixed ethnic
subjects) [16]. In addition, one hundred and eighty-two
Amerindians derived from two different groups (Guarani
and Tupinikin; Aracruz Indian Reserve, Espirito Santo
State in the Southeast Brazilian coast) were also ana-
lyzed. The study protocol was approved by the involved
Institutional Ethics Committees and National Ethic
Committee for Human Research (CONEP Register
Number 4599), and written informed consent was
obtained from all participants prior to entering the
study.
Genotyping
Genomic DNA from subjects was extracted from per-
ipheral blood following standard salting-out procedure
[17]. Genotypes for the SLCO1B1 rs4149056 (c.T521C,
p.V174A, exon 5) and SLCO1B1 rs4363657 (g.T89595C,
intron 11) polymorphisms were detected by polymerase
chain reaction (PCR) followed by high resolution melt-
ing (HRM) analysis with the Rotor Gene 6000
® instru-
ment (Qiagen, Courtaboeuf, France) [18-20]. The
QIAgility
® (Qiagen, Courtaboeuf, France), an automated
instrument, was used according to instructions to opti-
mize the sample preparation step (approximately 30
minutes). One specific disc is able to genotype 96 sam-
ples for these polymorphisms.
Amplification of the fragments was performed using the
primer sense 5’-TTGTTTAAAGGAATCTGGGTCA-3’
and antisense 5’-GAGTCTCCCCTATTCCACGA-3’ (77
pairs base) for the rs4149056; and sense 5’-
GAGTCCTTCTTTCTCAATTTTTCA-3’ and antisense
5’-AAAAGCCCTAGACCAAATGC-3’ (107 pairs base) for
the rs4363657. A 35-cycle PCR was carried out with the
following conditions: denaturation of the template DNA
for first cycle of 94°C for 120 s, denaturation of 94°C for
20 s, annealing of 53.4°C (rs4149056) or of 50.5°C
(rs4363657) for 20 s, and extension of 72°C for 22 s. PCR
was performed using a 10 μL reactive solution (10 mM
Tris-HCl, 50 mM KCl, pH 9.0; 2.0 mM MgCl2;2 0 0μMo f
each dNTP; 0.5 U Taq DNA Polymerase; 200 nM of each
primer; 10 ng of genomic DNA template) with addition of
fluorescent DNA-intercalating SYTO9
® (1.5 μM; Invitro-
gen, Carlsbad, USA).
In the HRM phase, the Rotor Gene 6000
® measured
the fluorescence in each 0.1°C temperature increase in
the range of 70-79°C (rs4149056) or of 68-77°C
(rs4363657). Melting curve were generated by the
decrease in fluorescence with the increase in the tem-
perature; and in analysis, nucleotide changes result in
three different curve patterns (Figure 1). Samples of the
three observed curves were analyzed using bidirectional
sequencing as a validation procedure (ABI Terminator
Sequencing Kit
® and ABI 3500XL Sequencer
® - Applied
Biosystems, Foster City, CA, USA). The two methods
gave identical results in all tests. The wild-type, hetero-
zygous and mutant homozygous genotypes for the
rs4149056 and rs4363657 could be easily discernible by
HRM analysis. In addition, 4% of the samples were ran-
domly selected and reanalyzed as quality controls and
gave identical results.
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Chi-square test was performed for comparative analysis
of the SLCO1B1 polymorphism frequencies according to
ethnicity (African descent, Mulatto, Caucasian descent,
and Amerindian). Chi-square test was also performed
for the comparative analysis between our data and pre-
vious reports. Hardy-Weinberg equilibrium and linkage
disequilibrium analyses were conducted with Haploview
4.0. All statistical analyses were carried out using the
SPSS software (v. 16.0), with the level of significance set
at p < 0.05.
Results
General data of the studied population sample
Of the 1,214 subjects (mean age 43.1 ± 14.2), 647
(53.3%) were female and 567 (46.7%) male. Ethnic group
distribution was: African descent 8.0% (n = 97), Mulatto
27.3% (n = 332), Caucasian descent 49.7% (n = 603),
and Amerindians 15.0% (n = 182).
Frequencies of the SLCO1B1 polymorphisms
The frequencies of the SLCO1B1 rs4149056 C variant
allele and of the homozygous genotype (CC) were
higher in Amerindians (28.3% and 9.9%) and were lower
in African descent subjects (5.7% and 0%) compared
with Mulatto (14.9% and 2.4%) and Caucasian descent
(14.8% and 4.1%) ethnic groups (p < 0.001 and p <
0.001, respectively) (Table 1).
The frequencies of the SLCO1B1 rs4363657 C variant
allele and of the homozygous genotype (CC) were also
higher in Amerindians (26.1% and 6.6%) and were lower
in African descent subjects (10.8% and 0%) compared
with Mulatto (18.2% and 1.5%) and Caucasian descent
(15.4% and 2.7%) ethnic groups (p < 0.001 and p <
0.001, respectively) (Table 1).
The genotypic distributions for the SLCO1B1
rs4149056 and rs4363657 polymorphisms were in
Hardy-Weinberg equilibrium according to ethnic
groups.
N
o
r
m
a
l
i
z
e
d

F
l
u
o
r
e
s
c
e
n
c
e

(
%
)
Temperature(°C)
70.0 73.0 76.0 79.0
0
25
50
75
100
N
o
r
m
a
l
i
s
e
d

F
l
u
o
r
e
s
c
e
n
c
e

b
y

g
e
n
o
t
y
p
e

2
Temperature(°C)
70.0 73.0 76.0 79.0
F
l
u
o
r
e
s
c
e
n
c
e

(
d
F
/
d
T
)
Temperature(°C)
70.0 79.0
AB
1 2 3
2
1
3 C
1
3
2
Figure 1 Graphs of the SLCO1B1 rs4149056 (c.T521C, exon 5) nucleotide changes results in different curve patterns using high
resolution melting analysis. A: Graph of normalized fluorescence by temperature. B: Graph of normalized fluorescence (based on genotype 2)
by temperature. C: Graph of melting curve analysis (fluorescence differential/temperature differential). 1: wild-type genotype (TT); 2: heterozygous
genotype (TC); 3: homozygous genotype (CC) for the SLCO1B1 rs4149056 polymorphism. The curve patterns for the SLCO1B1 rs4363657
polymorphism (g.T89595C, intron 11) were similar to curve patterns of rs4149056.
Table 1 Allelic and genotypic frequencies for the SLCO1B1 polymorphisms according to ethnic groups
Nucleotide Change and Genotype African descent Mulatto Caucasian descent Amerindian p value
n (100%) 97 332 603 182
SLCO1B1 rs4149056
TT 86 (88.7%) 241 (72.6%) 449 (74.5%) 97 (53.3%) < 0.001
TC 11 (11.3%) 83 (25.0%) 129 (21.4%) 67 (36.8%)
CC 0 8 (2.4%) 25 (4.1%) 18 (9.9%)
C allele 5.7% 14.9% 14.8% 28.3% < 0.001
SLCO1B1 rs4363657
TT 76 (78.4%) 216 (65.1%) 433 (71.8%) 99 (54.4%) < 0.001
TC 21 (21.6%) 111 (33.4%) 154 (25.5%) 71 (39.0%)
CC 0 5 (1.5%) 16 (2.7%) 12 (6.6%)
C allele 10.8% 18.2% 15.4% 26.1% < 0.001
SLCO1B1 rs4149056: c.T521C, p.V174A (exon 5); SLCO1B1 rs4363657: g.T89595C (intron 11).
Mulatto group was composed of mixed ethnicity subjects.
p values were calculated using Chi-square test.
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rs4149056 and rs4363657 variant alleles according to
ethnic groups
Linkage disequilibrium analysis show that the SLCO1B1
rs4149056 and rs4363657 variant alleles are in different
linkage disequilibrium patterns depending on ethnic ori-
gin (African descent: 89; Mulatto: 81; Caucasian descent:
68; Amerindian: 64) (Figure 2).
Discussion
The main finding of the present study was to observe
significant differences between the allelic and genotypic
frequencies of SLCO1B1 rs4149056 polymorphism asso-
ciated with statin-induced myopathy, according to ethni-
city in the Brazilian general population. To our
knowledge this is the first study indicating that Brazilian
Amerindians present higher frequencies of rs4149056 C
variant allele (28.3%) and probably higher risk for statin-
induced myopathy. These findings could be useful in
the strategic planning of the implementation of pharma-
cogenetic testing according to ethnicity.
The SLCO1B1 rs4149056 C variant allele frequency
found in our study was higher (p < 0.001) in Amerin-
dian subjects (28.3%) compared with other ethnic
groups and with Turkish [21] (12.2%); English [9]
(13.0%); European American [22] (14.3%); and German
[21] (15.0%) subjects. However, the Caucasian descent
(14.8%) and Mulatto (14.9%) ethnic groups of our study
presented similar (p > 0.050) rs4149056 C variant allele
frequency compared with Caucasian descent subjects
from Europe and USA. In addition, our African descent
( 5 . 7 % )s u b j e c tg r o u ph a ds i m i l a r( p>0 . 0 5 0 )f r e q u e n c y
compared with African American [22] (2.3%), Uganda
African [21] (3.9%), and Tanzania [23] (6.0%) subjects.
Interestingly, the frequency observed for the Mulatto
subjects indicates that the Amerindian ancestry may be
present in this multi-ethnic group, besides the presence
of known African ancestry.
For the SLCO1B1 rs4363657 polymorphism, C allele
frequency found in Caucasian descent in our study
(15.4%) was similar (p > 0.050) to that reported in Eng-
lish subjects (13.0%) who participated as controls in a
A
Linkage disequilibrium and haplotype analysis
C B D
Figure 2 Linkage disequilibrium and haplotype analysis for the SLCO1B1 rs4149056 and rs4363657 polymorphisms in the African
descent (A), Mulatto (B), Caucasian descent (C), and Amerindian (D) groups.
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Page 4 of 6genome-wide association study (GWAS) [9]. The non-
coding rs4363657 polymorphism was in nearly complete
linkage disequilibrium (LD = 97) with the non-synon-
ymous rs4149056 polymorphism, in the population sam-
ple in which the cited GWAS was performed [9]. In our
population sample plus Amerindians, it is possible to
observe that the SLCO1B1 rs4149056 and rs4363657 are
in different linkage disequilibrium patterns depending
on the ethnic origin. The African descent (LD = 89) and
Mulatto (LD = 81) ethnic groups present higher degree
of linkage disequilibrium. This highlights two main
points: first, even with the different linkage disequili-
brium among ethnic groups, the haplotype analysis are
not need because only the rs4149056 polymorphism
have been described as functional [11,24]. Second, the
different frequencies among ethnic groups for the poly-
morphisms used as markers in the GWAS platforms are
limitations/peculiarities of the GWAS methodology [25],
which may be acting as interferents in replication stu-
dies, mainly in countries with admixed population.
The association between SLCO1B1 rs4149056 with
myopathy (odds ratio: 4.5 - 95% CI 2.6 to 7.7, per copy
of the C allele; and odds ratio: 16.9 - 95% CI 4.7 to 61.1,
among CC homozygotes as compared with TT geno-
types) was observed in 85 subjects with myopathy taking
80 mg of simvastatin daily as part of a trial involving
12,000 participants; plus replication in a trial of 40 mg
of simvastatin daily involving 20,000 participants [9].
The authors of this GWAS plus replication study con-
cluded that common variants in the SLCO1B1 gene are
strongly associated with an increased risk of statin-
induced myopathy and genotyping may help to obtain
benefits of statin therapy more safely and effectively [9].
Other studies were performed to replicate this associa-
tion. Brunham et al observed that rs4149056 genotype
was significantly associated (odds ratio 2.3 per C allele)
with myopathy in patients receiving simvastatin (mean
~30 mg daily), but not in patients who received atorvas-
tatin [8]. In this way, genotype CC individuals compared
with wild-type TT individuals, the area under the
plasma concentration time curve for simvastatin acid
was increased 221% and for atorvastatin was increased
145% [12,13]. Voora et al confirmed, in 99 subjects with
statin-related adverse events, the association previously
identified, but also expanded this finding to the most
commom statin-induced side effects (e.g., myalgia or
muscle ache without significant creatine kinase eleva-
tions) [10]. Puccetti et al reported the same association,
but in a group of 46 subjects affected by familial
hypercholesterolemia treated with atorvastatin and
developing myopathy [26].
There are potential limitations in our study. First, the
self-referred ethnicity could be creating wrong separa-
tion. However, this form of classification is the one
most probable to be encountered in real-life situations
in the clinical practice. In addition, even self-referred
ethnicity was able to clearly differentiate groups of indi-
viduals with rather different allele and genotype fre-
quencies. Second, in order to implement a genotyping
program in this context, some points could still be eval-
uated, for example: other genetic markers, primary dis-
ease, use of concomitant medications, types of statins,
age and gender [11].
Conclusion
Our findings indicate interethnic differences for the
SLCO1B1 rs4149056 C risk allele frequency among
Brazilian general population plus Amerindians. Recent
studies indicated the genotyping for this functional
polymorphism as an important clinical tool in future
patient-tailored programs. Data of the present study
will be useful in the development of effective pro-
grams for stratifying individuals regarding adherence,
efficacy and choice of statin-type for patients who
need statin, specially in high-dose (e.g., familial
hypercholesterolemia).
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